About US
Contact us
-
Greece’s corruption prosecutor quits, citing pressure over Novartis bribery probeNovartis is embroiled in a soap opera in Greece, complete with bribery allegations and a suicide threat. Now the plot is thickening. The country’s chief corruption prosecutor, Eleni Raikou, has resign2017/4/11
-
Appeals court ruling resurrects 5,000 lawsuits tied to Merck & Co. Fosamax dangersThree years after a federal judge dismissed about 5,000lawsuits by patients claiming Merck & Co.’s osteoporosis drug Fosamax was responsible for their femur fractures, a higher court says Merck wi2017/4/11
-
Sanofi, Regeneron ask court to shield Dupixent from Amgen patent attackThe last time Sanofi and Regeneron launched a drug together, Amgen sued for patent infringement. Now, with an FDA decision on their key drug Dupixent due next week, the development partners are making2017/4/10
-
Judge in Japan lets Novartis off the hook in advertising scandalNovartis has escaped a false advertising charge in Japan tied to questionable data on its heart drug Diovan. It was one of a series of missteps for the Swiss company that culminated in a 15-daysuspens2017/4/10
-
Did Emflaza's DMD approval expose cracks at the FDA? Lawmakers want to knowAfter lambasting Marathon Pharma for its pricing strategy on a decades-old med recently approved to treat Duchenne muscular dystrophy, Sen. Bernie Sanders and Rep. Elijah Cummings are turning their fi2017/4/7
-
Zostavax patients sue Merck, claiming shingles shot caused injuries and deathMerck & Co. could have a growing Zostavax problem on its hands. After several plaintiffs filed lawsuits claiming the drugmaker’s shingles vaccine caused serious injury and death, attorneys say mor2017/4/7
-
Roche's Herceptin one step closer to biosim battle with Mylan licensing dealMylan and partner Biocon cleared another hurdle with their version of Roche’s breast cancer med Herceptin, one of the biggest biosim targets in the market. To wrap up their patent dispute, Roche will2017/4/6
-
Surprised shareholders target Allergan over generics pricing probeAllergan no longer ownsActavis, having unloaded the generics unit to Teva. That hasn't kept the drugmaker from facing potential fallout from shareholders who say Allergan’s share price has been stung2017/4/6
-
BOTH CRODA’S UNITED STATES SITES RECEIVE EXCiPACT GMPBrussels, 04 April, 2017EXCiPACT asbl is delighted to announce that both Croda Inc. manufacturing sites in the USA have recently beenawarded an EXCiPACT Certificate from SGS, one of EXCIPACT’s interna2017/4/5
-
FMC Corporation Announces Acquisition of Significant Portion of DuPont's Crop Protection Business; Simultaneous Sale of Health and Nutrition to DuPont- FMC will acquire the portion ofDuPont'sCrop Protection business required to be divested by aEuropean Commissionruling related toDuPont'smerger withThe Dow Chemical Company. -DuPontwill acquireFMC2017/4/1